

Nerve Agent / Organophosphate Poisoning	
The incident commander is in charge of the scene and you are to follow his/her direction for entering and exiting the scene. Patients in the hot and warm zones MUST be decontaminated prior to entering the cold zone.	
ADULT	PEDIATRIC
BLS Procedures	
Patients that are exhibiting obvious signs of exposure (SLUDGEM) of organophosphate exposure and/or nerve agents	
Maintain airway and position of comfort	
Administer oxygen as indicated	
<ul style="list-style-type: none"> • Mark I or DuoDote Antidote Kit <ul style="list-style-type: none"> ○ Mild Exposure: IM x 1 ○ Moderate Exposure: IM x1 <ul style="list-style-type: none"> • May repeat in 10 minutes if symptoms persist ○ Severe Exposure: IM x 3 in rapid succession, rotating injection sites 	
ALS Prior to Base Hospital Contact	
<p><i>Patient's that are exhibiting obvious signs of exposure (SLUDGEM) of Organophosphate exposure and/or Nerve Agents</i> <i>If not already administered by BLS personnel:</i></p> <ul style="list-style-type: none"> • Mark I or DuoDote Antidote Kit <ul style="list-style-type: none"> ○ Mild Exposure: IM x 1 ○ Moderate Exposure: IM x1 <ul style="list-style-type: none"> • May repeat in 10 minutes if symptoms persist ○ Severe Exposure: IM x 3 in rapid succession, rotating injection sites <p><u>For seizures:</u></p> <ul style="list-style-type: none"> • Midazolam <ul style="list-style-type: none"> ○ IV/IO – 2 mg <ul style="list-style-type: none"> • Repeat 1 mg q 2 min as needed • Max 5 mg ○ IM – 0.1 mg/kg <ul style="list-style-type: none"> • Max 5 mg 	<p><i>Patient's that are exhibiting obvious signs of exposure (SLUDGEM) of Organophosphate exposure and/or Nerve Agents</i> <i>If not already administered by BLS personnel:</i></p> <ul style="list-style-type: none"> • Mark I or DuoDote Antidote Kit <ul style="list-style-type: none"> ○ Mild Exposure: IM x 1 ○ Moderate Exposure: IM x1 <ul style="list-style-type: none"> • May repeat in 10 minutes if symptoms persist ○ Severe Exposure: IM x 3 in rapid succession, rotating injection sites <p><u>For seizures:</u></p> <ul style="list-style-type: none"> • Midazolam <ul style="list-style-type: none"> ○ IM – 0.1 mg/kg <ul style="list-style-type: none"> • Max 5 mg
Base Hospital Orders Only	
Consult with ED Physician for further treatment measures	
<ul style="list-style-type: none"> • Refer to VCEMS Policy 705.18-Overdose/Poisoning for organophosphate poisoning treatment guidelines. • DuoDote contains 2.1 mg Atropine Sulfate and 600 mg Pralidoxime Chloride. • Diazepam is available in the CHEMPACK and may be deployed in the event of a nerve agent exposure. Paramedics may administer diazepam using the following dosages for the treatment of seizures: <ul style="list-style-type: none"> ○ Adult: 5 mg IM/IV/IO q 10 min titrated to effect (<i>max 30 mg</i>) ○ Pediatric: 0.1 mg/kg IV/IM/IO (max initial dose 5 mg) over 2-3 min q 10 min titrated to effect (<i>max total dose 10 mg</i>) • Mild exposure with symptoms: <ul style="list-style-type: none"> ○ Miosis, rhinorrhea, drooling, sweating, blurred vision, nausea, bradypnea or tachypnea, nervousness, fatigue, minor memory disturbances, irritability, unexplained tearing, wheezing, tachycardia, bradycardia • Moderate exposure with symptoms: <ul style="list-style-type: none"> ○ Miosis, rhinorrhea, SOB, wheezing, secretions, soft muscle weakness and fasciculations, GI effects • Severe exposure with symptoms: <ul style="list-style-type: none"> ○ Strange confused behavior, severe difficulty breathing, twitching, unconsciousness, seizing, flaccid, apnea pinpoint pupils involuntary defecation, urination 	

Effective Date: June 1, 2018
Next Review Date: April 30, 2020

Date Revised: April 12, 2018
Last Reviewed: April 12, 2018


 VCEMS Medical Director